ArticleScientific reports2023
A circulating microRNA panel as a novel dynamic monitor for oral squamous cell carcinoma.
Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 21 citations in OpenAlex.
- Integrated analysis identified MARK4 as a prognostic and immunomodulatory biomarker in oral squamous cell carcinoma.Oncology letters · 2026Article
- Emerging Diagnostic Strategies for Oral Cancer and Oral Potentially Malignant Disorders: A PRISMA-Guided Scoping Review.Diagnostics (Basel, Switzerland) · 2026Review
- Extracellular vesicles as regulators of chemotherapy resistance in oral squamous cell carcinoma.Discover oncology · 2026Review
- Review
- Comparative Meta-Analysis: Salivary, Plasma, and Serum miRNA Profiles for Oral Squamous Cell Carcinoma Detection.Journal of personalized medicine · 2026Review
- Unlocking the power of non-coding RNAs: toward real-time cancer monitoring in precision oncology.Molecular cancer · 2026Review
- Current and Emerging Protein Biomarkers for the Diagnosis and Prognosis of Head and Neck Cancer.Genes · 2025Review
- The relationship of human tissue MicroRNAs with those from cerebrospinal fluid, tear, sweat, semen, and saliva.Scientific reports · 2025Article
- Identification of a Novel Salivary Four-miRNA Signature for Non-Invasive Diagnosis of Oral Squamous Cell Carcinoma.International journal of molecular sciences · 2025Article
- SLC8A1-AS1 inhibits oral squamous cell carcinoma by regulating the miR-1305/ESRRG axis.Discover oncology · 2025Article
- The role of miR-92b-3p in notch signaling and monitoring of oral squamous cell carcinoma.Oncogene · 2025Article
- Recent advances in biomarker detection of oral squamous cell carcinoma.Frontiers in oncology · 2025Review
- Tissue microRNA dynamics in sinonasal inverted papilloma: implications for pathology and therapy.Tissue barriers · 2025Review
- Extracellular Vesicle microRNAs as Possible Liquid Biopsy Markers in HNSCC-A Longitudinal, Monocentric Study.Cancers · 2024Article
- LncRNA NR2F2-AS1 inhibits the progression of oral squamous cell carcinoma by mediating the miR-32-5p/SEMA3A axis.The Kaohsiung journal of medical sciences · 2024Article
- Article
- Oral Squamous Cell Carcinoma: Focus on Biomarkers for Screening.Journal of dentistry (Shiraz, Iran) · 2024Review
- An ELISA Test Able to Predict the Development of Oral Cancer: The Significance of the Interplay between Steroid Receptors and the EGF Receptor for Early Diagnosis.Diagnostics (Basel, Switzerland) · 2023Article
- Oral Squamous Cell Carcinoma and Concomitant Primary Tumors, What Do We Know? A Review of the Literature.Current oncology (Toronto, Ont.) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oral squamous cell carcinoma (OSCC) has high recurrence and mortality rates despite advances in diagnosis and treatment. Therefore, it is necessary to identify new biomarkers for early detection, efficient monitoring, and prognosis prediction. Since microRNA (miRNA) is stable and detectable in serum, it has been reported to inform the diagnosis and monitor disease progression through liquid biopsy. In this study, a circulating specific miRNA panel in OSCC patients was developed, and its usefulness as a dynamic monitor was validated. Small RNAs were extracted from the serum of OSCC patients (n = 4) and normal controls (n = 6) and profiled using next-generation sequencing. NGS identified 42 differentially expressed miRNAs (DEmiRNAs) in serum between patients with OSCC and healthy controls, with threefold differences (p < 0.05). Combining the 42 DEmiRNAs and The Cancer Genome Atlas (TCGA) databases OSCC cohort, 9 overlapping DEmiRNAs were screened out. Finally, 4 significantly up-regulated miRNAs (miR-92a-3p, miR-92b-3p, miR-320c and miR-629-5p) were identified from OSCC patients via validation in the Chungnam National University Hospital cohort. Application of the specific miRNA panel for distinguishing OSCC patients from healthy controls produced specificity and sensitivity of 97.8 and 74%, respectively. In addition, the serum levels of these 4 miRNAs significantly decreased after complete surgical resection and increased after recurrence. We suggest that circulating 4-miRNA panel might be promising non-invasive predictors for diagnosing and monitoring the progression of patients with OSCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.